1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: a cancer journal for clinicians. 2020;70(1):7-30.
2. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
3. Baker E, Whiteoak N, Hall L, France J, Wilson D, Bhaskar P. Mammaglobin-A, VEGFR3, and Ki67 in Human Breast Cancer Pathology and Five Year Survival. Breast cancer : basic and clinical research. 2019;13:1178223419858957.
4. Gallardo A, Garcia-Valdecasas B, Murata P, et al. Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis. Breast cancer research and treatment. 2018;167(1):31-37.
5. Kilickap S, Kaya Y, Yucel B, Tuncer E, Babacan NA, Elagoz S. Higher Ki67 expression is associates with unfavorable prognostic factors and shorter survival in breast cancer. Asian Pacific journal of cancer prevention : APJCP. 2014;15(3):1381-1385.
6. Ishihara M, Mukai H, Nagai S, et al. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival. Oncology. 2013;84(3):135-140.
7. Acs B, Zambo V, Vizkeleti L, et al. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy. Diagn Pathol. 2017;12:1-12.
8. Chakraborty D, Basu S, Ulaner GA, Alavi A, Kumar R. Diagnostic Role of Fluorodeoxyglucose PET in Breast Cancer: A History to Current Application. PET clinics. 2018;13(3):355-361.
9. Kitajima K, Miyoshi Y, Sekine T, et al. Harmonized pretreatment quantitative volume-based FDG-PET/CT parameters for prognosis of stage I-III breast cancer: Multicenter study. Oncotarget. 2021;12(2):95-105.
10. Kitajima K, Miyoshi Y, Sekine T, et al. Harmonized pretreatment quantitative volume-based (18)F-FDG PET/CT parameters for stage IV breast cancer prognosis. Multicenter study in Japan. Hellenic journal of nuclear medicine. 2020;23(3):272-289.
11. Gelezhe PB, Blokhin IA, Marapov DI, Morozov SP. Quantitative parameters of MRI and (18)F-FDG PET/CT in the prediction of breast cancer prognosis and molecular type: an original study. American journal of nuclear medicine and molecular imaging. 2020;10(6):279-292.
12. Qu YH, Long N, Ran C, Sun J. The correlation of (18)F-FDG PET/CT metabolic parameters, clinicopathological factors, and prognosis in breast cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2021;23(3):620-627.
13. Tagliafico AS, Piana M, Schenone D, Lai R, Massone AM, Houssami N. Overview of radiomics in breast cancer diagnosis and prognostication. Breast. 2020;49:74-80.
14. Waks AG, Winer EP. Breast Cancer Treatment A Review. Jama-Journal Of the American Medical Association. 2019;321(3):288-300.
15. Antunovic L, Gallivanone F, Sollini M, et al. [(18)F]FDG PET/CT features for the molecular characterization of primary breast tumors. European journal of nuclear medicine and molecular imaging. 2017;44(12):1945-1954.
16. Khare S, Singh SS, Irrinki S, et al. (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Features in Locally Advanced Breast Cancer and Their Correlation with Molecular Subtypes. Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India. 2018;33(4):290-294.
17. van Griethuysen JJM, Fedorov A, Parmar C, et al. Computational Radiomics System to Decode the Radiographic Phenotype. Cancer research. 2017;77(21):e104-e107.
18. Mohamadien NRA, Sayed MHM. Correlation between semiquantitative and volumetric 18F-FDG PET/computed tomography parameters and Ki-67 expression in breast cancer. Nucl Med Commun. 2021.
19. Deng SM, Zhang W, Zhang B, Chen YY, Li JH, Wu YW. Correlation between the Uptake of F-18-Fluorodeoxyglucose (F-18-FDG) and the Expression of Proliferation-Associated Antigen Ki-67 in Cancer Patients: A Meta-Analysis. Plos One. 2015;10(6).
20. Acar E, Turgut B, Yigit S, Kaya G. Comparison of the volumetric and radiomics findings of 18F-FDG PET/CT images with immunohistochemical prognostic factors in local/locally advanced breast cancer. Nucl Med Commun. 2019;40(7):764-772.